BEVERLY HILLS, Calif.— The liquid is dark red, a mixture of fat and blood, and Dr. Mark Berman pumps it out of the patient's backside. The number of stem-cell clinics across the United States has surged from a handful in 2010 to more than 170 today, according to figures compiled by The Associated Press.» Read More
Brewing price sensitivity in the sector, compounded with expensive valuations, led to the selloff in U.S. biotech stocks, says Peter Boockvar, Chief Market Analyst at The Lindsey Group.
Express Scripts' decision to drop Gilead's Sovaldi treatment sparked fears that pharmaceutical firms may have to bow to pricing pressure moving forward, says Andrew McDonald, Co-Portfolio Manager at BioShares Funds.
CNBC's Bob Pisani is tracking the action in biotech stocks into the end of the year. CNBC's Bertha Coombs, provides perspective.
After Express Scripts exclusively selected AbbVie over Gilead and JNJ for its hepatitis C drug, CNBC's Meg Tirrell discusses how the news has impacted the entire biotech industry.
Mark Fisher, MBF Clearing Corp. chairman, shares his favorite stock in the biotech space.
CNBC's Jim Cramer and David Faber discuss Express Scripts' selection of AbbVie over Gilead for its hepatitis C drug and what this means for Gilead.
"We're trying to develop treatments that offer new hope or patients battling cancer," says Hans Bishop, Juno Therapeutics CEO, explaining the technology behind Juno.
Because of its anti-coagulant drug, FXI, Mad Money's Jim Cramer thinks Isis Pharmaceuticals can climb much higher.
*Decision marks win for International Stem Cell Corp. BRUSSELS/ LONDON, Dec 18- Europe's top court has opened the door to certain stem cell patents in the European Union by ruling that an organism incapable of developing into a human being is not a human embryo and may be patented. Thursday's judgment by the European Court of Justice was made following a case...
CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about exciting new drugs emerging from Celgene's pipeline and the progress being made with Multiple myeloma.
Two stocks you need to watch ahead of San Francisco's 56th ASH hematology conference, with CNBC's Meg Tirrell.
Discussing some of the best stocks in the biotech industry going into 2015, with Michael Yee, RBC Capital Markets.
CNBC's Meg Tirrell provides insight to Biogen Idec's promising early study on its experimental medicine for Alzheimer's disease. Michael Yee, RBC Capital Markets, explains why the stock is headed higher from here.
Biogen's Alzheimer's drug has shown promise in studies, with CNBC's Meg Tirrell.
A Google-backed service to map DNA and identify potential risk factors for some diseases has been launched in the U.K., months after it was banned in the U.S..
Sachin Shah, Analyst at Albert Fried and Company, discusses news that botox maker Allergan agreed to a $66 billion takeover bid from Actavis.
Prostate cancer drug developer Dendreon has filed for Chapter 11 bankruptcy protection. CNBC's Meg Tirrell takes a close look at what contributed to the company's downfall.
CNBC's Meg Tirrell speaks to Alex Gorsky, Johnson & Johnson chairman & CEO, about helping military veterans transition from the battlefield into corporate America.
Jack Lief, Arena Pharmaceutical president & CEO, breaks down the company's Q3 earnings and discusses the outlook for its weight loss drug "Belviq."
Russia has a new tech city chock-full of co-working spaces, seed funding, and a research university. All they need now are the technologists.